• J&J opens €72M vaccine plant for stepped-up R&D fiercepharma
    December 04, 2018
    Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing has to measure up. The small plant acquired in its Crucell purchase just won't support its advancing pipeline candidates—and certainly not product launches down the road.
PharmaSources Customer Service